Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in Chinese Patients with DME
NCT04058067Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2019
- Primary completion
- Jan 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in diabetic macular edema (DME), sponsored by Novartis. Started Aug 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04058067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058067.